The present address of Dr. B. Halliwell is Department of Biochemistry, National University of Singapore, Kent Ridge Crescent, Singapore, 119260.
F4 - Isoprostanes as Specific Marker of Docosahexaenoic Acid Peroxidation in Alzheimer's Disease
Article first published online: 1 MAY 2002
Journal of Neurochemistry
Volume 72, Issue 2, pages 734–740, February 1999
How to Cite
Nourooz-Zadeh, J., Liu, E. H. C., Yhlen, B., Änggåard, E. E. and Halliwell, B. (1999), F4 - Isoprostanes as Specific Marker of Docosahexaenoic Acid Peroxidation in Alzheimer's Disease. Journal of Neurochemistry, 72: 734–740. doi: 10.1046/j.1471-4159.1999.0720734.x
Abbreviations used : AAPH, 2,2' -azobis(2-amidinopropane) ; AD, Alzheimer's disease ; BHT, butylated hydroxytoluene ; DHA, docosahexaenoic acid ; GC-MS, gas chromatography-mass spectroscopy ; NBB, N-butylboronate ; NICI, negative ion chemical ionisation ; PFB, pentafluorobenzyl bromate ; PG, prostaglandin ; PMI, postmortem interval ; TMS, trimethylsilane.
- Issue published online: 1 MAY 2002
- Article first published online: 1 MAY 2002
- Docosahexaenoic acid;
- Alzheimer's disease;
- Lipid peroxidation;
- Arachidonic acid
Abstract : F2-isoprostanes are prostaglandin-like compounds derived from free radical-catalysed peroxidation of arachidonic acid. Peroxidation of eicosapentaenoic acid produces F3-isoprostanes, whereas peroxidation of docosahexaenoic acid would give F4-isoprostanes. This study demonstrates the presence of esterified F4-isoprostanes in human brain and shows that levels are elevated in certain brain cortex regions in Alzheimer's disease. Our data with Alzheimer's disease suggest that analysis of F4-isoprostanes will provide new opportunities to study lipid peroxidation in the neurodegenerative diseases.